
Wisconsin Essential Diabetes Mellitus Care Guidelines 2004



Tools and Resources Included

TABLE OF CONTENTS

ACKNOWLEDGMENTS	V
INTRODUCTION	IX
DISCLAIMER	XI
SUMMARY OF UPDATES	XII
WISCONSIN ESSENTIAL DIABETES MELLITUS CARE GUIDELINES, 2004 (ONE-PAGE)	XIII
SECTION 1: GENERAL RECOMMENDATIONS/CARE	1-1
BODY MASS INDEX (BMI) TABLE FOR ADULTS	1-7
SECTION 2: SELF-MANAGEMENT EDUCATION	2-1
DIABETES SELF-MANAGEMENT BEHAVIOR GOALS WITH GRAPHICS DIABETES SELF-MANAGEMENT BEHAVIOR GOALS WITHOUT GRAPHICS AMERICAN DIABETES ASSOCIATION RECOGNIZED DIABETES EDUCATION PROGRAMS IN WISCONSIN DIABETES SELF-MANAGEMENT EDUCATION RECORD DIABETES PATIENT FLOW SHEET/CHART AUDIT TOOL	2-8 2-9 2-11
SECTION 3: MEDICAL NUTRITION THERAPY	3-1
MEAL PLANNING WITH THE PLATE METHOD: LUNCH/DINNERSEVEN WAYS TO SIZE UP YOUR SERVINGS	
SECTION 4: GLYCEMIC CONTROL	4-1
ALGORITHM 1 – TYPE 2 DIABETES: GLYCEMIC CONTROL DIABETES MEDICATIONS UPDATE – 2004 INSULIN 2004 DIABETES SICK DAYS PLAN	4-11 4-15
SECTION 5: CARDIOVASCULAR CARE	5-1
PREVENTING CARDIOVASCULAR EVENTS IN PERSONS AT RISK OR WITH ESTABLISHED CV DISEASE	5-13
SECTION 6: KIDNEY CARE	6-1
ALGORITHM 2 – SCREENING AND INITIAL RECOMMENDATIONS FOR DIABETIC KIDNEY DISEASE (MICROALBUMINURIA AND MACROALBUMINURIA)	6-6
SECTION 7: EYE CARE	
DIABETES EYE EXAM CONSULTATION FORM	7-4
SECTION 8: FOOT CARE	8-1
ALGORITHM 3 – DIABETIC FOOT DISORDERS ULCER: A CLINICAL PRACTICE PATHWAY ALGORITHM 4 – DIABETIC FOOT DISORDERS INFECTION: A CLINICAL PRACTICE PATHWAY ALGORITHM 5 – DIABETIC FOOT DISORDERS CHARCOT FOOT: A CLINICAL PRACTICE PATHWAY ANNUAL COMPREHENSIVE DIABETES FOOT EXAM FORM MONOFILAMENT APPLICATION INSTRUCTIONS SHOES AND SOCKS OFF POSTER – ENGLISH SHOES AND SOCKS OFF POSTER – SPANISH HIGH-RISK FOOT STICKERS	8-8 8-9 8-10 8-11 8-12 8-13

SECTION 9: ORAL CARE	9-1	
Interdisciplinary Diabetes Dental Referral Form		
DIABETES ORAL HEALTH SCREENING GUIDE	9-6	
SECTION 10: EMOTIONAL/SEXUAL HEALTH CARE	10-1	
PATIENT HEALTH QUESTIONNAIRE (PHQ-9)	10-7	
PHQ-9 QUICK DEPRESSION ASSESSMENT – INSTRUCTIONS FOR USE	10-8	
SECTION 11: INFLUENZA AND PNEUMOCOCCAL IMMUNIZATIONS	11-1	
SECTION 12: PRECONCEPTION AND PREGNANCY CARE	12-1	
SECTION 13: SCREENING FOR PRE-DIABETES AND DIABETES	13-1	
ALGORITHM 6: SCREENING FOR PRE-DIABETES AND DIABETES	13-8	
MEDICAL NUTRITION THERAPY FOR PRE-DIABETES AND METABOLIC SYNDROME		
SECTION 14: QUALITY IMPROVEMENT MODELS AND ACTION STEPS	14-1	

ACKNOWLEDGMENTS

The authors of these Guidelines, the Wisconsin Diabetes Advisory Group and other dedicated individuals, represent key organizations committed to improving diabetes care in Wisconsin. Many other individuals were also involved in the review and revision of various drafts. The Wisconsin Diabetes Prevention and Control Program wishes to thank them for their collaboration, expertise, and perseverance regarding this statewide project.

Guideline Revision Workgroup Members

Mary Anderson

Wisconsin Association for Perinatal Care Preconception and Prenatal Care Committee

Ruth Ann Berkholtz, MSSW, BCD

Licensed Clinical Social Worker, Madison Psychiatric Associates

Dory Blobner, RN, MS, CDE Diabetes Education Coordinator

Dean Clinic

Mary Bruskewitz, RN, MS Wisconsin Nurses Association

Capitol Area and Surrounding Communities

Association of Diabetes Educators (CASCADE)

Jenny Camponeschi, MS

Diabetes Prevention and Control Program

Wisconsin Department of Health and Family Services

Pat Celek, RN, CDE Aurora Health Care

Ann Conway, RN, MS, MPA

Executive Director, Wisconsin Association for Perinatal Care

Susan Davidson, MD St. Mary's Hospital

Sarah Dillenbeck, RD, CD, CDE UW Medical Foundation

Robert Draeger Retired Teacher

Sherree Drezner, ACSW, LCSW

University of Wisconsin Hospital and Clinics

Krista Eastman, BA Consultant

April Eddy, RN, CNS, CDE Meriter Hospital, Perinatal Clinic Ann Ebert, PharmD

Wisconsin Association for Perinatal Care Preconception and Prenatal Care Committee

Diane Elson, MD

University of Wisconsin Hospital and Clinics

Joan Fisher, RN, CCM MercyCare Insurance Company

Irene Golembiewski, MA Media Solutions

University of Wisconsin Medical School

Margo Grady, MS, CGC

Wisconsin Association for Perinatal Care

Chair, Preconception and Prenatal Care Committee

Meriter Hospital

Rosalyn Haase, RD/CD, CDE, MPH, BC-ADM

Wisconsin Dietetic Association

Peter G. Hanson, MD

Peter Christiansen Health Center

Dee Helgeson, RN, CDE Reedsburg Physicians Group

Sonja Henry, MS, CGC

Wisconsin Association for Perinatal Care Preconception and Prenatal Care Committee

Dan Hopfensperger Immunization Program

Wisconsin Department of Health and Family Services

Sue Hugl, RN, BSN, CDE

Froedtert and Medical College Diabetes Care Center

Anthony M. Iacopino, DMD, PhD Wisconsin Dental Association

Marquette University School of Dentistry

Jonathan B. Jaffery, MD

University of Wisconsin Medical School Department of Medicine, Section of Nephrology Kate Jaeger

Diabetes Program Assistant, Sixteenth Street Community Health Center

Mary Jenny, RN, BSN

Population Health Care Coordinator

WEA Trust

Audrey Johnson, RN, MSN, CDE

Aurora Health Care

Virginia Jordan, MS, RD, CDE

West Central Wisconsin Association of Diabetes Educators (WECWAADE)

Pamela Kittleson, RPh UW Medical Foundation

Kevin P. Kortsch, DPM

Wisconsin Society of Podiatric Medicine

Christy Kreul

Physicians Plus Insurance Corporation

Leah Ludlum, RN, BSN, CDE

Diabetes Prevention and Control Program

Wisconsin Department of Health and Family Services

Steven B. Magill, MD, PhD St. Luke's Medical Center Aurora Health Care

Glenna McWilliams Board Certified Pedorthist National Pedorthic Services, Inc.

Melissa Meredith, MD

University of Wisconsin Hospital and Clinics

Kristi Michalowski, MS, CPHQ

MetaStar, Inc.

Kyle Mounts, MD

Neonatologist, Newborn Care Physicians of Southeast Wisconsin

Jane Nelson Worel, RN, MS University of Wisconsin Hospital and Clinics

Preventive Cardiology Program

Paul M. Reber, DO

Dean Medical Center

Chandra Reddy, MD, MPH

Great Lakes Inter-Tribal Council, Inc.

Thomas Repas, MD

Affinity Medical Group, Department of Endocrinology

Tim Ringhand, RN, MPH

Diabetes Prevention and Control Program

Wisconsin Department of Health and Family Services

Fredric J. Romm, MD, MPH Medical College of Wisconsin

Elaine Rosenblatt, NP

University of Wisconsin Hospital and Clinics

David A. Scheidt, OD

Wisconsin Optometric Association

Eva Scheppa, RN, BSN

Family Health Center of Marshfield

Marshfield Clinic

Julie Schuller, MD, MPH

Medical Director, Sixteenth Street Community Health

Center

Elizabeth Spencer, RD, MS, CDE

UW Health Eau Claire Family Medicine Clinic

University of Wisconsin, Department of Family Medicine

Thomas S. Stevens, MD

Wisconsin Academy of Ophthalmology

Alisa Sunness, RD, CDE

UW Medical Foundation

Julie Thiel, RPh

Pharmacy Society of Wisconsin

Gail Underbakke, MS, RD

University of Wisconsin Hospital and Clinics

Preventive Cardiology Program

University of Wisconsin Medical Foundation

Behavioral Health Consultation Services

William Weis, DPM, FACFAS, DWS

Wisconsin Society of Podiatric Medicine

Jennifer Wilen, MPH

Learning Coordinator, Wisconsin Association for Perinatal

Care

Susan Williams, RN, CDE

Nurse Diabetes Educator

St. Francis Hospital

Kara Yaeger, RN, CDE

University of Wisconsin Hospital and Clinics

Other Wisconsin Diabetes Advisory Group Members and Contributors

Rafael Acevedo

Latino Health Organiation

Jane M. Aldridge Purity Corporation

Della Alvarez, MS, FNP, APNP Manager Employee Special Services

SC Johnson Inc.

Diane Anderson, MS, RN, CS, FNP, CDE

Gateway Technical College Aurora Medical Group

Lori Arnoldussen, RN

Clinical Quality Coordinator, Disease Management and

Prevention

Thedacare Health System

Darlene Balke

Thedacare Health System

Jessica Bennett, RN

Ignace Indian Health Center

Elliot Blackdeer Ho-Chunk Nation

Mary Jo Brink, MS, RN Cardiovascular Health Program

Wisconsin Department of Health and Family Services

Mariaelena Chang Calhoun Childrens Speciality Group Medical College of Wisconsin

Mary Carlson

Wisconsin Physicians Service

Diane Dappern

Broadway Healthcare and E-Health Technology

Yolanda Garza

Council on Latino Health

Catherine M. Girard

Executive Director, American Diabetes Association,

Wisconsin Area

Tina Gissal Bayer

Yvonne Greer, MPH, RD, CD

Milwaukee Department of Public Health

Victoria Griffin

Bureau of Quality Assurance

Wisconsin Department of Health and Family Services

Dean Groth, MS Pfizer, Inc.

Kate Holzum

Children's Hospital of Wisconsin

Cindy Huber

Executive Director, National Kidney Foundation of

Wisconsin

David Hughes, PharmD, CDE

University of Wisconsin, School of Pharmacy

Tito Izard, MD

University of Wisconsin Medical School Aurora Sinai Family Care Center

Bob Johnson, MD

Wisconsin Academy of Family Physicians

Western Wisconsin Medical Associates – River Falls

Medical Clinic

Kelli Jones

Milwaukee Area Health Education Center

Jennifer Keeley, MS, RD

Bureau of Aging and Long Term Care Resources Wisconsin Department of Health and Family Services

Greg Khvalabov, RMMAE

BD Medical

Diabetes Health Care

Stephen R. Knapp

ProMark Communications, Inc.

Jim Lazarz

CUNA Mutual Group

Mary Kay Lingeman, RN, MBA

Aurora Health Care

Cheryl Luria GlaxoSmithKline

Suzanne Matthew, PhD

Executive Director, Northern Wisconsin Area Health

Education Center (NAHEC)

Patricia McManus, PhD Black Health Coalition

Traci Meyer

Prevent Blindness Wisconsin

Christine Miller, RN, PhD

University of Wisconsin School of Nursing

Michael Nelipovich, RHD Bureau for the Blind

Wisconsin Department of Health and Family Services

Ruth Norton, RN, CDE

North East Wisconsin Association of Diabetes Educators

Victoria O'Brien

American Heart Association

Daniel Patterson, RN, BSN Managed Health Services

Mary Pesik, RD, CD

Nutrition and Physical Activity Program

Wisconsin Department of Health and Family Services

Richard Pomo

Executive Director, Wisconsin Council of the Blind

Patrick L. Remington, MD, MPH

Professor, Department of Population Health Sciences

Dana Richardson, RN, BSN, MAB-HSA Wisconsin Hospital Association

Ray Ropers

Wisconsin Lions Foundation, Wisconsin Lions Diabetes Focus Group

Ann Ruelle, RD, CDE Advanced Health Care

Kathaleen Rust

Unity Health Insurance

Cynthia Schlough The Alliance

(Employer Health Care Alliance Cooperative)

Geraldine Schrader

Brown County Health Department

Debbie Scullin, HH, RN FAMHS Home Health Agency

Shirley Sharp, BS, MA Director, Youth and Family Services

Milwaukee Urban League, Inc.

Heather Silbaugh, BS, CHES

Wisconsin Primary Health Care Association

Terry Spears Barnett, MD Aurora Medical Group

Robert Stone-Newsom, PhD

Wisconsin Public Health and Health Policy Institute

Nancy Tarantino

American Diabetes Association, Wisconsin Market

Patricia Tellez-Giron, MD

Assistant Professor, University of Wisconsin

Department of Family Medicine Chair, Latino Health Council

Chou Thao

Board President, United Refugee Service

Melissa Tobler, RN, BSN

Palmer & Cay

Michelle Urban, MD

Chief Medical Officer, Division of Health Care Financing

Department of Health and Family Services

Vaughn Vance

WEA Trust

Denise Walbrandt Pigarelli, PharmD, BC-ADM

Pharmacy Society of Wisconsin

University of Wisconsin School of Pharmacy

Katie Walsh, RN, CDE Animas Corporation

Anita Wasserburger, RN

Clinical QI Nurse, Security Health Plan of Wisconsin

Lynne Wentz, RN, MHS, CDE

Novo Nordisk Pharmaceuticals, Inc.

Char White

Wisconsin Office of Rural Health

INTRODUCTION

Diabetes is a serious, common, costly, yet controllable disease affecting over 329,000 adults in Wisconsin. People with diabetes are at increased risk of diabetes-related complications, including blindness, kidney disease, foot and leg amputations, cardiovascular disease, stroke, and oral infections and diseases. Many of these complications can be prevented, or at least delayed, by optimizing glycemic control and providing ongoing preventive care to include early identification of problems, intervention, and treatment. Despite clinical knowledge of the benefits of optimal glycemic control and preventive care, current studies show that many people with diabetes do not receive such care. This is due to a variety of attitudinal, educational, and systemic barriers. The adoption of the Wisconsin Essential Diabetes Mellitus Care Guidelines (Guidelines) provides one means of improving care and enhancing quality of life for people with diabetes and is a growing feature in many health care practices. Quality improvement initiatives offer another promising strategy to make dramatic improvements in overall health outcomes.

These Guidelines, originally published in 1998 and revised in 2001, were recently again revised to incorporate the latest scientific evidence regarding good diabetes care. The Wisconsin Diabetes Advisory Group, a committee of over 80 key statewide organizations and other health care professionals, collaborated with the Wisconsin Diabetes Prevention and Control Program staff to update the 2004 Guidelines. The target audience for the Guidelines includes primary care providers and many other health care professionals and health systems (e.g., managed care organizations, other insurers, clinics, purchasers, etc.). Based on clinical trials, accepted science, and expert opinions, the Guidelines provide a concise, general framework for the care and prevention of diabetes-related complications.

The following national studies have been instrumental in shaping previous versions of the Guidelines and continue to shape the current Guidelines version for Wisconsin. Each is summarized below:

Diabetes Control and Complications Trial

In a 1993 landmark study, the Diabetes Control and Complications Trial (DCCT) demonstrated that optimal glycemic control in an intensively treated group delayed the onset of microvascular complications (i.e., retinopathy, nephropathy, and neuropathy) and slowed the progression of complications already present in people with Type 1 diabetes. The benefits of sustained lowering of blood glucose levels were seen for all people regardless of age, sex, duration of diabetes, or history of poor control. While this trial promoted optimal glycemic control to achieve desired results, reduction in risk was noted even when blood glucose was not reduced to normal levels. For each two percent decrease in A1c, there was a 50-75% reduction in complications. Furthermore, there was no threshold level of A1c for this effect. A follow-up study indicated that the reduction in risk for microvascular changes lasted for at least four years after the DCCT ended, despite increasing blood glucose levels. Although optimal glycemic control is not appropriate for all people, almost all people are candidates for better control. Any improvement in glycemic control may help decrease the risk of complications.

United Kingdom Prospective Diabetes Study

In 1998, the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that improved blood glucose control reduced the risk of microvascular complications in people with Type 2 diabetes. For every percentage point decrease in A1c there was a 35% reduction in the risk of these complications. Additional data from this study showed that treatment of high blood pressure also reduced microvascular complications, congestive heart failure, and cardiovascular accident risk. Of further importance in this study are the data indicating that nearly 50% of people at diagnosis had one or more complications of diabetes, demonstrating the need for early diagnosis and treatment of diabetes mellitus.

Diabetes Prevention Program

The Diabetes Prevention Program (DPP) was a large, randomized clinical trial designed to test whether lifestyle modifications or medications could prevent or delay the development of Type 2 diabetes in high risk individuals (i.e., those with fasting plasma glucose values > 95 mg/dL and impaired glucose tolerance). Participants were randomized into one of three intervention groups comparing: 1) intensive lifestyle changes consisting of diet and physical activity, 2) treatment with the oral diabetes drug metformin, 3) placebo (a control group that took placebo pills). The second and third groups also received standard information on diet and physical activity. The DPP was discontinued a year early (2001), because the data had clearly answered the main research questions. The risk of developing diabetes was reduced by 58% in the lifestyle group and by 31% in the medication group, compared to those in the placebo group. This study, together with other smaller studies in China and Finland, demonstrated that Type 2 diabetes can be delayed or prevented in people at risk of Type 2 diabetes regardless of ethnic background. Benefit was markedly increased in people over the age of 60. Lifestyle intervention is therefore proven to be extremely helpful in reducing the risk of developing Type 2 diabetes.

DISCLAIMER

These Guidelines are designed to serve as a tool for supporting and influencing those health care provider decisions that promote and provide consistent, comprehensive, preventive care. With the goal of improving care system-wide, the Guidelines include recommended lab tests, exams, medical checks, and essential education. This document is divided into 14 sections, each providing a quick guide of pertinent information and references. Helpful tools and resources are included at the end of each section to assist providers with integrating the Guidelines into everyday practice. The Guidelines are population-based and therefore intended to be appropriate for most people with diabetes, but not intended to define the optimal level of care that an individual person may need. Clinical judgment may indicate the need for adjustments appropriate to the needs of each particular person (e.g., age, medical condition, or individual glycemic control goal). These Guidelines are an evolving process and, as such, will be reviewed periodically and revised to reflect advances in research and medical knowledge.

SUMMARY OF UPDATES

Section	Updates/Additions				
General	✓ Assess physical activity at each visit				
Recommendations/	Two helpful tools added: 1) Growth Chart – Boys Body Mass Index-for-age Percentiles, 2 to 20 years				
Care (page 1-1)	and 2) Growth Chart – Girls Body Mass Index-for-age Percentiles, 2 to 20 years				
Self-Management	Expanded text includes seven key self-care behaviors for diabetes self-management education core				
Education (page 2-1)	outcomes outcomes				
Education (page 2-1)					
	Revised Diabetes Patient Flow Sheet/Chart Audit Tool				
	Four helpful tools added: 1 & 2) Diabetes Self-Management Behavior Goal Sheets, 3) List of ADA				
N. 11. 1 N. 1 . 1 . 1	Recognized Programs in Wisconsin, and 4) Diabetes Self-Management Education Record				
Medical Nutrition	Expanded text includes nutrition strategies for non-dieticians				
Therapy (page 3-1) Two helpful tools added: 1) Meal Planning with the Plate Method: Lunch/Dinner and 2					
	Size Up Your Servings				
Glycemic Control	<u>Expanded text</u>				
(page 4-1)	Four helpful tools added: 1) Algorithm – Type 2 Diabetes: Glycemic Control, 2) Diabetes Medications				
	Update – 2004, 3) Insulin 2004, and 4) Diabetes Sick Days Plan				
Cardiovascular Care	✓ Expanded text				
(page 5-1)	✓ Lipid profile: added total cholesterol and non-HDL-cholesterol current levels				
	✓ Goals updated for:				
	• Total Cholesterol < 200 mg/dL				
	• Triglycerides < 150 mg/dL				
	• HDL \geq 40 mg/dL (men), HDL \geq 50 mg/dL (women)				
	• Non-HDL (Cholesterol) < 130 mg/dL				
	• LDL < 100mg/dL (optimal goal), LDL < 70 mg/dL (for very high risk)				
	✓ Blood pressure < 130/80 mmHg				
	✓ Smoking status – expanded resources				
	✓ Aspirin prophylaxis dose change				
	✓ One helpful tool added: Preventing Cardiovascular Events in Persons at Risk or with Established CV				
	Disease				
Kidney Care	✓ Expanded text				
(page 6-1)					
(page o 1)	✓ Albumin/creatinine ratio using a spot urine to screen for microalbuminuria ✓ Serum creatinine annually				
	✓ Estimated GFR annually and kidney staging				
	✓ One helpful tool added: Algorithm – Screening and Initial Recommendations for Diabetic Kidney				
F G (7.1)	Disease 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				
Eye Care (page 7-1)	Expanded text includes the two exceptions to the annual dilated eye exam				
Foot Care (page 8-1)	Expanded text includes information on peripheral arterial disease (PAD)				
	Four helpful tools added: 1) Algorithm – Diabetic Foot Disorders ULCER: A Clinical Practice Pathway,				
	2) Algorithm – Diabetic Foot Disorders INFECTION: A Clinical Practice Pathway, 3) Algorithm –				
	Diabetic Foot Disorders CHARCOT FOOT: A Clinical Practice Pathway, and 4) Monofilament				
	Application Instructions				
Oral Health Care	✓ Updated text				
(page 9-1)	✓ One helpful tool added: Interdisciplinary Diabetes Dental Referral Form				
Emotional /Sexual	✓ New section				
Health (page 10-1)	✓ One helpful tool added: Patient Health Questionnaire (PHQ-9) with instructions				
Immunizations	✓ Updated text				
(page 11-1)					
Preconception and	✓ Expanded and reorganized text				
Pregnancy Care					
(page 12-1)					
Screening for Pre-	✓ New section				
diabetes and	Two helpful tools added: 1) Algorithm: Screening for Pre-diabetes and Diabetes and 2) Medical				
In: 1 / 12.1)					
Diabetes (page 13-1)	Nutrition Therapy for Pre-diabetes and Metabolic Syndrome				

Periodic updates will be made to these Guidelines and will be posted on the Wisconsin Diabetes Prevention and Control Program web page, on the Wisconsin Department of Health and Family Services web site:

http://dhfs.wisconsin.gov/health/diabetes/DBMCGuidelns.htm

WISCONSIN ESSENTIAL DIABETES MELLITUS CARE GUIDELINES, 2004 (ONE-PAGE)

The recommendations in these Essential Diabetes Mellitus Care Guidelines are intended to serve as a guide for clinicians and others involved in the implementation of care and preventive services for people with diabetes. They are not intended to replace or preclude clinical judgement. Abnormal physical or lab findings should result in follow-up/intervention.

For particular details and references for each specific area, please refer to the supporting documents and implementation tools in the full-text guideline available via the Internet at http://dhfs.wisconsin.gov/health/diabetes/DBMCGuidelns.htm or telephone: (608) 261-6871.

Concerns	Care/Test	Frequency		
General	♦ Perform diabetes-focused visit	Type 1*: Every 3 months		
Recommendations/		<u>Type 2*</u> : Every 3 – 6 months		
Care		* consider more often if A1c ≥ 7.0% and/or complications exist		
	Review management plan, assess problems and goals	Each focused visit; revise as needed		
	♦ Assess physical activity	Each focused visit		
CIENT	◆ Assess nutrition/weight/BMI/growth	Each focused visit		
Self-Management Education	 Refer to diabetes educator, preferably a certified diabetes educator (CDE); curriculum to include the ten 			
Education	key areas of the national standards for diabetes self-			
	management education	At diagnosis, then every 6 – 12 months, or more as needed		
Medical Nutrition	◆ Refer to registered dietician, preferably a CDE; to	Type 1: At diagnosis; then, if age < 18, every 3 – 6 months;		
Therapy	include areas defined by the American Dietetic	if age \geq 18, every 6 – 12 months.		
	Association's Nutrition Practice Guidelines	<u>Type 2</u> : At diagnosis; then every $6 - 12$ months or more as needed		
Glycemic Control	♦ Check A1c (see Algorithm 1)	<u>Type 1</u> : Every 3 months		
	Goal: $< 7.0\%$ or $\le 1\%$ above lab norms	<u>Type 2</u> : Every 3 – 6 months		
	• Review goals, meds, side effects, and frequency of	F 1.6 1 1 1		
	hypoglycemia	Each focused visit		
	♦ Assess self-blood glucose monitoring schedule	Each focused visit, 2 – 4 times/day, or as recommended		
Cardiovascular	♦ Check lipid profile	<u>Children</u> : If > 2 years, after diagnosis and once glycemic control is		
Care	Adult goals: Total Cholesterol < 200 mg/dL	established. Repeat annually if abnormal. Follow National Cholesterol Education Program (NCEP III) guidelines.		
	Triglycerides $< 150 \text{ mg/dL}$ $\text{HDL} \ge 40 \text{ mg/dL (men)}$	Adults: Annually. If abnormal, follow NCEP III guidelines.		
	$HDL \ge 40 \text{ mg/dL (men)}$ $HDL \ge 50 \text{ mg/dL (women)}$	Amidally. If abhormal, follow IVCEI III guidelines.		
	Non-HDL (Cholesterol) < 130 mg/dL			
	LDL < 100 mg/dL (optimal goal)			
	LDL < 70 mg/dL (for very high risk)			
	♦ Blood pressure	Each focused visit		
	Adult goal: < 130/80 mmHg			
	Pediatric goal: below 90% of ideal for age Assess smoking status			
	Assess smoking status Start aspirin prophylaxis (unless contraindicated)	Each visit; if smoker, counsel to stop; refer to cessation Age > 40 with diabetes; Age ≤ 40, individualize based on risk		
Kidney Care	◆ Check albumin/creatinine ratio using a random urine	rige > 40 with diabetes, rige 2 40, individualize based on risk		
Triumey cure	sample, also called urine microalbumin/creatinine	<u>Type 1</u> : Begin with puberty or after 5 years duration, then annually <u>Type 2</u> : At diagnosis, then annually		
	ratio (see Algorithm 2)			
	♦ Check serum creatinine	At diagnosis, then annually		
	♦ Perform routine urinalysis	At diagnosis, then as indicated		
Eye Care	◆ Perform dilated eye exam by an ophthalmologist or	<u>Type 1</u> : If age ≥ 10 , within $3-5$ years of onset, then annually		
	optometrist			
Foot Care	◆ Inspect feet, with shoes and socks off	Section 7)		
root Care	Perform comprehensive lower extremity exam	Annually, with monofilament		
Oral Care	Perform comprehensive lower extremity exam: Perform oral health screening	At diagnosis, then each focused visit		
orar care	◆ Advise dental exam by general dentist or periodontal	At diagnosis, then each focused visit		
	specialist			
		(if edentate)		
	♦ Assess emotional health; screen for depression	Each focused visit		
Health Care	♦ Assess sexual health concerns	Each focused visit		
Immunizations	◆ Provide influenza vaccine	Annually, if age ≥ 6 months		
	◆ Provide pneumococcal vaccine	Once; then per Advisory Committee on Immunization Practices		
Preconception and		3 – 4 months prior to conception*		
Pregnancy Care	♦ Assess contraception/discuss family planning			
	◆ Screen for gestational diabetes			
		women during pregnancy		
Screening for	♦ Perform fasting plasma glucose test or oral glucose	Test all people \geq age 45; if normal and person has no risk factors,		
Pre-diabetes and	tolerance test (see Algorithm 6)	retest in 3 years		
Diabetes		(SEE BACK)		

Screening for Pre-diabetes and Diabetes

Test all people \geq 45 years for pre-diabetes and diabetes. If screening results are normal and person has no risk factors, re-testing should occur at 3-year intervals. Screen at a younger age or more often if the person has one or more risk factors from the following list:

- 1) Body mass index (BMI) \geq 25 kg/m²
- 2) Sedentary lifestyle
- 3) Prior history of pre-diabetes/glucose intolerance
- 4) Race/ethnicity (e.g., African-Americans, Hispanic-Americans, Native Americans, Asian-Americans, and Pacific Islanders)
- 5) Family history of diabetes in one or more first-degree relatives
- 6) History of hypertension (>140/90 mmHg)
- 7) History of vascular disease
- 8) History of dyslipidemia: $HDL \le 35 \text{ mg/dL}$ and/or a triglyceride level $\ge 250 \text{ mg/dL}$
- 9) Markers of insulin resistance: (e.g., acanthosis nigricans and/or waist circumference > 40 inches in men and > 35 inches in women)
- 10) History of polycystic ovary syndrome (PCOS)
- 11) History of gestational diabetes mellitus (GDM) in women or delivery of a baby weighing more than nine pounds at birth

Table 1: Diagnosis of Pre-diabetes and Diabetes (2004 Criteria)

	<u> </u>	Oral Glucose Tolerance	Random/Casual Plasma
Test	(FPG)	Test (OGTT)	Glucose (with symptoms)
How Performed	Blood glucose is	75-gram glucose load	Blood glucose is measured
	measured after at least an	(drink) is ingested after	at any time regardless of
	8 hour fast	at least an 8 hour fast;	eating
		blood glucose is measured	
		at 2 hours	
Normal	< 100 mg/dL	< 140 mg/dL	
Pre-diabetes (IFG)	100 - 125 mg/dL		
Pre-diabetes (IGT)		140 – 199 mg/dL	
Diabetes Mellitus	≥ 126 mg/dL *	$\geq 200 \text{ mg/dL}$	$\geq 200 \text{ mg/dL} \Leftrightarrow \mathbb{H}$ (with symptoms)

IFG: Impaired fasting glucose

IGT: Impaired glucose tolerance

It is not appropriate to have a person eat a meal and then draw a random glucose two hours after

^{*} Test must be confirmed by repeating on a different day